Previous 10 | Next 10 |
Editor's note: Seeking Alpha is proud to welcome Theodore Zucconi as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » NanoStri...
CytoDyn ( OTCQB:CYDY ) announces that new data show that weekly doses of 525 mg and 700 mg of leronlimab (PRO 140) in HIV-1-positive patients produced a 90% response rate in patients who passed the first 10 weeks of monotherapy without virologic failure. More news on: CytoDyn Inc., Healt...
New data suggests that 525 mg dose and 700 mg dose responders’ rates are approximately 90% for those HIV patients who pass first 10 weeks of monotherapy without virologic failure CytoDyn has engaged top CCR5 expert, Bruce Patterson M.D., former Medical Director of Virology at Sta...
I have been hesitant about buying into Progenics Pharmaceuticals ( PGNX ) due to my insufficient knowledge about the advancements of radiopharmaceuticals in the oncology arena. Perhaps it is all the hype of immuno-oncology and the rise of gene therapy that caused me to believe that radiopharma...
VANCOUVER, Washington, March 18, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, to...
VANCOUVER, Washington, March 11, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”) a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced th...
VANCOUVER, Washington, March 04, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the FDA has reviewed and accepted Cyto...
VANCOUVER, Washington, Feb. 27, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY ), a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that data from its study of leronlimab (PRO 140) is schedule...
CytoDyn ( CYDY ) is a full fledged penny stock with an exciting story to tell. The premise of this posting is that it has so much sizzle that it is entirely too hot to handle. I am staying away, at least for the time being. CytoDyn plans on its paradigm shifting PRO 140 rapidly taking a majo...
VANCOUVER, Washington, Feb. 20, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that it was able to reduce by more than 98% the incidence of human breast cance...
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...